The pathogenesis of Alzheimer's disease is characterized by aggregation of the amyloid-β protein (Aβ) into neurotoxic plaques. Recent in vivo studies have suggested the non-proteolytic clearance of Aβ via receptormediated transport across the blood-brain barrier (BBB). The aim of this study was to investigate the role of P-glycoprotein (Pgp) and the low-density lipoprotein receptor-related protein (LRP) in Aβ efflux across the BBB. We developed an in vitro BBB-like model using MadinDarby Canine Kidney (MDCK) cells seeded on filters separating apical (blood) and basolateral (brain) compartments. MDCK cells were stably transfected with Pgp or mLRP4, an LRP mini-receptor. When compared to empty vector-transfected cells, MDCK-Pgp cells did not transcytose radiolabeled Aβ in the basolateral-to-apical direction. MDCK-mLRP4 cells were found to endocytose and degrade, but not to trasncytose intact radiolabeled Aβ. These results implicate LRP as a mediator of Aβ degradation, but indicate that overexpression of LRP or Pgp alone is insufficient for non-proteolytic transcytosis of intact Aβ.
Introduction
Alzheimer's disease (AD) is the most common cause of dementia, with over 30 million people affected world-wide. A key neuropathological lesion in AD, the neuritic plaque, consists of extracellular deposits of the amyloid-β protein (Aβ). Accumulation of Aβ is believed to initiate AD when there is an imbalance between its production and clearance, leading to its aggregation into oligomers and neuritic plaques (Hardy and Selkoe, 2002) .
Research into therapeutic avenues to lower cerebral Aβ levels has largely centered on decreasing its production by inhibiting the proteases that generate Aβ (Selkoe and Schenk, 2003) , increasing its clearance through immunotherapy (Weiner and Frenkel, 2006) , or promoting its degradation by proteases such as insulin-degrading enzyme and neprilysin (Tanzi et al., 2004) . In addition, non-proteolytic clearance by receptor-mediated transport of Aβ out of the CNS has been investigated as another potential mechanism for decreasing cerebral Aβ load. Two pathways for Aβ transport out of the CNS exist: bulk flow (Silverberg et al., 2003) of interstitial fluid (ISF) into the blood via the cerebrospinal fluid (CSF), and transcytosis of Aβ across the blood-brain barrier (BBB). It has been reported that CSF-mediated bulk flow accounts for no more than 10-15% of non-proteolytic transport of Aβ out of the CNS in vivo (Shibata et al., 2000) , leaving the BBB as the main route of efflux. The BBB is distinct from other cell barriers by its increased tight junction density, lower rates of non-selective pinocytosis, lack of fenestrations, and unique cell surface receptor expression profile (Rubin and Staddon, 1999) . A few such receptors for Aβ transport have been described (Zlokovic, 2004) .
Low-density lipoprotein receptor-related protein (LRP) is ã 600 kDa multi-ligand cell surface receptor that is highly expressed in brain and contains four extracellular ligand-binding domains (designated I-IV). Over 30 different ligands for LRP have been reported and include the classes: lipoproteins, coagulation factors, growth factors, extracellular matrix proteins, chaperones, and bacterial/viral proteins. The majority of LRP ligands bind to domains II and IV with equal affinity (Cam and Bu, 2006) . Investigation into LRP's role in AD was stimulated by genetic evidence linking the LRP gene to late-onset AD (Kang et al., 1997) . Zlokovic and colleagues first reported LRP's effects on Aβ efflux, showing that the in vivo clearance of radiolabeled Aβ peptides injected into the brains of mice was inhibited by coinjection with the endogenous inhibitor receptor-associated peptide (RAP) and by an anti-LRP antibody (Shibata et al., 2000) . In vivo studies of LRP's potential for effluxing Aβ are promising, but they do not identify the biochemical mechanism of the apparent transcytosis of intact Aβ across the endothelial cells of the BBB.
